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Abstract: As the overall prognosis and treatment response rate to standard chemotherapy 
for acute myeloid leukemia (AML) remains poor in the older adult population, there is a 
need for more effective therapeutic agents with lower toxicity proﬁ  les that can be offered to 
these patients. Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody that was 
approved by the US Food and Drug Administration for use as monotherapy in patients 60 
years of age and older with relapsed AML. GO consists of a humanized anti-CD33 antibody 
(hP67.6) which is linked to N-acetyl-γ calicheamicin 1,2-dimethyl hydrazine dichloride. Once 
the antibody attaches to the surface antigen, it is rapidly internalized. Calicheamicin, a potent 
enediyne, is subsequently released and acts as a cytotoxic anti-tumor agent. In this population, 
GO has an acceptable toxicity and yields response rates approaching 30%. The efﬁ  cacy of GO 
as monotherapy and in combination therapy for treatment of both de novo and relapsed AML 
continues to be investigated.
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Background – acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common type of acute leukemia occurring 
in adults. There will be an estimated 13,290 new diagnoses in the United States in 2008, 
with a yearly, age-adjusted incidence rate of 3.6 per 100,000 people.1 The median age 
at diagnosis is approximately 67 years, and the incidence is rising, particularly in the 
“very old” (patients in their 8th and 9th decades of life), likely related to the aging 
population as a whole. Thus, the majority of AML is seen in older adults.
Initial treatment has not changed signiﬁ  cantly over the last 30 years. Standard 
regimens use cytarabine combined with anthracyclines or anthracenediones for remis-
sion induction, followed by cytarabine, alone or in combination, for post-remission 
therapy. Although there has been little change in chemotherapy regimen, supportive 
pharmacologic care (including antiemetics, and antibiotics) has improved signiﬁ  -
cantly and has made this chemotherapy more tolerable. The rate of relapse, however, 
remains high, and the overall outcome in older adult populations is poor. Conventional 
chemotherapy regimens induce complete remission (CR) in 65% to 85% of patients 
younger than 60 years of age.2–8 Of those achieving a CR, only 30% to 40% can expect 
long-term disease-free survival (DFS). In older adults (  60 years of age), results are 
even more dismal, with CR achievable in 40% to 55% of patients. Of those who do 
achieve a CR, only 10% to 20% are still alive 3 years out from diagnosis.4,9–11 This 
low chance of durable remission comes at a price of high treatment-related mortality 
(20% or higher compared to less than 10% in the younger adult population). A number 
of studies have explored more intensive up-front chemotherapy, addition of cytotoxic 
drugs, and even extended maintenance therapy, without demonstrable improvement in 
survival outcomes.12–15 Thus, for almost all older AML patients, therapy for relapsed 
disease will be a consideration.Clinical Interventions in Aging 2009:4 198
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Pathobiology of AML in older adults
Why the high relapse rate in older adults? As advances in 
molecular biology and genetics continue to develop, AML 
in the older adult population is increasingly recognized as 
having distinct biological features and disease characteristics 
from AML in younger adults.
In the older adult population, AML is more likely to arise 
from proximal bone marrow stem cell disorders (such as 
MDS) and with leukemia-speciﬁ  c abnormalities in more than 
one hematopoeitic cell lineage. Approximately 30% of older 
patients with de novo AML actually have evidence of trilineage 
myelodysplasia.17 Having an antecedent hematologic disorder 
is associated with poor response to chemotherapy, prolonged 
periods of cytopenia, lower CR and shorter duration of CR.
In older adults, there tends to be a higher incidence of 
poor-risk cytogenetic abnormalities, such as abnormalities of 
chromosomes 5, 7, 8, or complex cytogenetics, and multiple 
comorbidities. They are also less likely to have good-risk 
cytogenetic ﬁ  ndings, such as balanced, core-binding factor 
abnormalities, including t(8; 21); inv (16) and t(16; 16), involv-
ing CBFB-MYH11 chimeric product; and the PML-RARa 
mutation t(15; 17).18–22 Whether newly identiﬁ  ed molecular 
lesions such as the FMS-related tyrosine kinase 3 gene inter-
nal transmembrane duplications (FLT3 ITDs) and mutations 
of the nucleophosmin gene (NPM1) play a role in the older 
adult population of AML patients has yet to be determined, 
though preliminary data indicate these abnormalities may have 
even greater prognostic potential than the core binding factor 
abnormalities. Ultimately, however, older age seems to predict 
for higher rates of relapse and signiﬁ  cantly shorter OS.23
Secondary AML, which is less responsive to chemotherapy, 
also is more common in this age group, comprising between 
25% and 50% of cases, compared to  10% in younger adults. 
Secondary AML is associated with poorer outcomes.2,20,24
Finally, AML in the older adult population appears to be 
intrinsically more difﬁ  cult to treat, with a higher incidence of 
resistance to conventional chemotherapy. This is mediated by 
greater expression of genes that confer drug resistance, such as 
MDR1, the P-glycoprotein (gp170) chemotherapy efﬂ  ux pump, 
present in one study in 71% of myeloblasts in older adults, 
compared to only 35% of blasts in younger AML patients.21
Choosing therapy of older adults 
with AML
The difﬁ  cult decision
Because conventional chemotherapy has such dismal out-
comes in the older adult population and the treatment-related 
mortality and morbidity are so high, the decision of therapy 
in older adults can be a complicated and difﬁ  cult process, and 
as much as possible intensive therapy should be directed to 
speciﬁ  c molecular abnormalities, or avoided with particularly 
poor risk characteristics. One study explored the effect of 
time from diagnosis of AML to treatment initiation on CR 
and OS in over 1300 AML patients. The results showed that 
delaying therapy in older patients had no impact on these 
survival outcomes.25 Thus, older patients may beneﬁ  t from 
waiting for the results of additional testing to return, allowing 
enrollment into studies that account for cytogenetic ﬁ  ndings 
or that target molecular therapies.
Although indirect data support the use of intensive che-
motherapy in older patients (60 years or older), most will 
derive little beneﬁ  t from this approach. Only one randomized 
study, reported two decades ago, has ever shown a survival 
advantage of remission induction therapy (with daunorubicin, 
vincristine, and cytarabine) as compared to best supportive 
care. This trial noted a signiﬁ  cant median survival beneﬁ  t 
of only 10 weeks for patients receiving remission induction 
therapy.26 A more recent case-control study showed a survival 
advantage for giving intensive chemotherapy compared to 
best supportive care or low-dose approaches of 197 days vs 
53 days (hazard ration [HR] 1.88, p = 0.01).27
Because of high treatment-related mortality and poor 
outcomes, many older patients choose less aggressive 
therapy, often at the recommendation of their physicians. 
In a study by Ferrara, et al questionnaires were sent to 
32 hematologic institutions involved in the Gruppo Italiano 
per le Malattie Ematolgiche dell’Adulto (GIMEMA) group. 
The purpose of the study was to assess the various factors 
that inﬂ  uence therapeutic choice in the older population 
with relapsed AML. The most frequent factor found to 
inﬂ  uence therapeutic choice was performance status. Other 
additional factors included age   70 years, duration of CR1 
(  or  12 months), concomitant disease requiring speciﬁ  c 
treatment. It is interesting to note that other prognostic factors 
such as cytogenetics, serum LDH, previous MDS or white 
blood cell count were not considered as heavily in this older 
population.28 In older patients who are not ﬁ  t for aggressive 
care, Burnett et al have also demonstrated that low-dose 
ara-C treatment was superior to best supportive care and 
hydroxyurea in achieving CR.29
Therapy of relapsed AML 
in older adults
In the younger adult population, in the setting of relapsed dis-
ease, the goal is cure. Intensive, cytarabine-based chemotherapy Clinical Interventions in Aging 2009:4 199
Gemtuzumab ozogamicin for acute myeloid leukemia
salvage regimens with subsequent allogeneic hematopoietic 
stem cell transplantation remain preferred treatments. These 
approaches are likely to be too toxic in older adults with 
relapsed AML, in whom the goals of therapy can no longer 
be curative. In those older patients who are ﬁ  t enough and 
want to continue with treatment, according to National 
Comprehensive Cancer Network (NCCN) guidelines (for 
patients who are 60 years of age and older) the recommen-
dations for salvage therapy are enrollment in clinical trials, 
repetition of initial induction chemotherapy regimen (if the 
patient has already enjoyed a durable remission from that 
therapy), or gemtuzumab ozogamicin.
Gemtuzumab ozogamicin
Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal 
antibody that is conjugated to a cytotoxic agent, calicheami-
cin. It was approved by the FDA in May 2000 for use as 
single-agent therapy in elderly patients (patients   60 years 
old) with ﬁ  rst-recurrence CD33+ AML who are not candi-
dates for standard therapy. The approved dose is 9 mg/m2 
intravenously (given on days 1 and 15).
The CD33 antigen
The CD33 antigen is a transmembrane cell-surface glycopro-
tein (of unknown function) that is speciﬁ  c for myeloid cells. 
It is a member of the sialic acid-binding immunoglobulin-
like lectin (siglec) family. It is found on both mature and 
immature myeloid cells. It is found on erythroid, mega-
karyocytic, and multipotent progenitors. It is not present 
on normal pluripotent hematopoietic stems cells. Because 
it is absent on normal hematopoietic stem cells and has 
little expression in non-hematopoietic tissue, the CD33+ 
antigen is a reasonable target for monoclonal antibodies 
against AML.
CD33 is expressed on approximately 90% of myeloblasts 
in patients with AML, as deﬁ  ned by the presence of antigen 
on greater than 20% leukemic blasts. It is also found on 
leukemic blasts in a majority of patients with MDS. When 
CD33+ intensity was compared in patients with AML, it was 
found to be signiﬁ  cantly higher in patients  60 years of 
age compared to those who were older. However, levels of 
CD33+ intensity did not correlate with cytogenetics, response 
to therapy, or overall survival.30
GO pharmacology
GO is a humanized IgG4 anti-CD33 monoclonal antibody 
(hP67.6) conjugated to N-acetyl-γ calicheamicin dimethyl 
hydrazide, a derivative of calicheamicin.
The IgG4 isotype was chosen because it has the longest 
circulating half-life of all isotypes and is the least likely to 
participate in immune-mediated mechanisms like complement 
ﬁ  xation and antibody-dependent cellular toxicity. The hP67.6 
antibody is non-cytotoxic by itself. Calicheamicin is a natu-
rally occurring enediyne antibiotic isolated from actinomycete 
Micromonospora echinospora calichensis. Enediyne antibi-
otics are unique reactive compounds; once aromatized, they 
produce cytotoxic biradicals that cause phophodiester bond 
DNA breakage. This conjugation allows a favorable balance 
between hydrolytic stability in physiological buffers (pH 7.4) 
and efﬁ  cient drug release at pH of lysosomes (pH 4).
GO is internalized rapidly after infusion. The endocy-
tosed anti-CD33 complexes translocate to lysosomes where 
the acidic environment causes release of the calicheamicin 
derivative. A reactive intermediate of the caclicheamicin 
is formed through reduction by glutathione which causes 
double-strand breaks in DNA.
Gender and age do not appear to effect GO pharmacoki-
netics. There are no signiﬁ  cant differences between younger 
and older patients in terms of maximum concentration, time 
to maximum concentration, area under the curve, clearance, 
or volume of distribution of GO.31
GO as single-agent therapy in older 
patients with relapsed AML
In a phase 1 study by Sievers et al GO as a single agent was 
used to treat 40 patients with refractory or relapsed AML. The 
doses ranged from 0.25 to 9 mg/m2. Patients were included 
in the study if they had good performance status, a white 
blood cell count   30 × 109/L, and no evidence of renal or 
liver dysfunction. Of these patients, 18 had undergone prior 
allogeneic stem cell transplant. Twenty percent achieved a 
reduction in marrow blast count, with less than 5% blasts at 
morphologic exam. Toxicities were mostly infusion-related 
fevers and chills, and myelosuppression. Approximately 
20% of patients also developed mild elevations of liver 
transaminases.32
The study above then led to 3 open-label multicenter phase 
II trials, with GO given at a dose of 9 mg/m2 (see Table 1). 
Because the study designs, endpoints, patient demographics, 
and dosing schedules were similar, the patients were pooled 
together to attain a larger efﬁ  cacy population. From reports 
in 2001 by Sievers et al33 and by Larson et al in 2005,34 a 
total of 277 AML patients were enrolled. These patients were 
all in ﬁ  rst relapse and had evidence of CD33+ AML blasts. 
The median age was 61 years old. The primary end point 
was the number of patients attaining CR, and secondary end Clinical Interventions in Aging 2009:4 200
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points were the rates of complete remission with persistent 
thrombocytopenia (CRp), relapse-free survival (RFS), overall 
survival (OS), and time to platelet- and time to ANC recovery. 
The overall response rate was 26% (13% achieved CR and 
13% achieved CRp), with a median time to remission of 60 
days. Interestingly, there were no differences in response rates 
among patients stratiﬁ  ed by age or cytogenetic abnormalities. 
The median RFS was 6.4 months for patients who achieved 
CR and 4.5 months for patients who achieved a CRp. Toxici-
ties included infusion-related fevers and chills, myelosuppres-
sion, and about 30% of patients developed treatment-related 
infections and/or elevations of bilirubin and transaminases.
In a meta-analysis by Leopold et al, GO as monotherapy 
was compared to high-dose cytosine arabinoside (HiDAC) in 
patients with ﬁ  rst-relapse AML. The outcome of 128 patients 
historically treated with HiDAC-containing chemotherapy 
regimens were compared to 128 patients (enrolled in mul-
tiple phase II trials) who were treated with GO (9 mg/m2 on 
days 1 and 15). The median age of patients receiving GO 
was signiﬁ  cantly higher (60 years of age) than those treated 
with HiDAC (50 years of age). Of those receiving GO, 41% 
of patients achieved a CR or CRp. If the ﬁ  rst remission was 
between 10 and 19 months, there were no differences between 
the two groups for remission duration following treatment. 
However, if the ﬁ  rst remission duration was 3 to 10 months, 
then patients treated with GO had higher remission duration 
following treatment. Interestingly, there was no statistical dif-
ference between overall remission rates with GO or HiDAC 
containing chemotherapy regimens between the different 
cytogenetic groups. Interestingly, the analysis revealed that 
early death rate occurred with HiDAC if age was less than 
45 years, whereas lower early death rate resulted from GO 
therapy in patients who were greater than 75 years of age.35 
It is important to note that this was not a randomized study 
and the median ages of these two groups were signiﬁ  cantly 
different, likely reﬂ  ecting that few older patients are consid-
ered candidates for HiDAC.
Toxicity
GO is generally tolerated well. The most common infusion-
related reactions include chills, fevers, and hypotension that 
can occur acutely. In the pivotal phase II studies which led 
to FDA-approval of GO, Larson et al analyzed the efﬁ  cacy 
and safety of GO and found that the incidence of Grade 3 or 
4 infusion-related events included fevers (6%), chills (8%), 
hypotension (4%), nausea (3%), and hypertension (2%).34 
The hypotension occurred several hours after completion of 
infusion and was reversible with intravenous ﬂ  uid administra-
tion. The incidence of infusion-related events was lower on 
repeat administration. Preventive therapy with corticosteroids 
and acetaminophen and diphenhydramine were effective in 
reducing infusion related toxicities. There was no difference 
in incidence of infusion-related reactions between younger 
and older patients.
Myelosuppression was seen in the majority of patients. 
In phase II trials, grade 3 or 4 neutropenia was observed 
in 98% of patients. However, the incidence of grade 3 or 
4 sepsis (17%) and pneumonia (8%) was lower than would be 
expected. There was no signiﬁ  cant difference in the incidence 
of infections or in the median time to absolute neutrophil 
recovery (to 500/μL) between younger and older patients. 
Despite the observation of grade 3 or 4 thrombocytopenia in 
99% of patients, the overall incidence of grade 3 or 4 bleeding 
events was only 13%. In younger and older patients who 
achieved CR, platelet count to 25,000/μL occurred in a 
median of 35 days and 38 days, respectively. In younger 
and older patients who achieved a CRp, platelet count to 
25,000/μL occurred in 39 days and 72 days, respectively.34





GO dose CR/CRp Median OS 
(months)
RFS (months)
Larson et al34 277 61 (20–87) 9 mg/m2 on days 
1 and 14
13/13 4.9 (all patients) 
12.2 (CR patients) 
12.9 (CRp patients)
5.2 (all patients) 
6.4 (CR patients) 
4.5 (CRp patients)
Taksin et al56 57 64 (22–80) 3 mg/m2 on days 
1, 4, and 7
26/7 8.4 (all patients) 11 (all patients)
Piccaluga et al53 24 63 (20–75) Either 9 mg/m2 or 
6 mg/m2 for 3 days, 
at least 14 days apart
3/2 2 (all patients) –
Abbreviations: GO, gemtuzumab ozogamicin; CR, complete remission; CRp, complete remission with incomplete platelet recovery; OS, overall survival; RFS, relapse-free 
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Elevations in hepatic transaminases and bilirubin were 
also observed. These were mostly transient events. Grade 3 or 
4 hyperbilirubinemia occurred in 29% of patients, elevations in 
hepatic aspartate aminotransferase occurred in 18%, and eleva-
tions in alanine amino-trasnsferase in 9%. Veno-occlusive 
disease (VOD) occurred in 16 (5%) patients, eight patients died 
of this condition. Patients who undergo subsequent myeloabla-
tive HSCT were found to have higher incidence of developing 
VOD. There was no signiﬁ  cant difference in incidence of 
hepatotoxicity between younger and older patients.34
GO as combination therapy in older 
adults with relapsed AML
Several trials have evaluated efﬁ  cacy of GO in combina-
tion with cytotoxic chemotherapy as ﬁ  rst-line therapy, and 
for treating refractory/relapsed AML (see Table 2). GO 
has been studied in combination with cytosine arabinoside 
(ara-C) alone; idarubicin and ara-C; liposome-encapsulated 
daunorubicin, ara-C, and cyclosporine; ﬂ  udarabine, ara-C and 
cyclosporine; and others.36–40 The results have been variable, 
likely reﬂ  ecting the heterogeneity of these diseases.
In a phase II study by Tsimberidou et al the efﬁ  cacy of 
GO used in combination with ﬂ  udarabine, Ara-C, and cyclo-
sporine (MFAC) in patients with relapsed or refractory AML 
was investigated. The median age was 53 years, with 11 of 
the patients older than 60 years of age. Thirty-two patients 
were included in this study (34% with refractory disease, 
66% with relapsed AML). Nine (28%) patients achieved CR 
and 2 (6%) achieved CRp. Of those achieving CR or CRp, 
4 (36%) patients were 60 years or older. The median OS was 
5.3 months. Signiﬁ  cant side effects were grade 3 or 4 hyper-
bilirubinemia (44%), grade 3 or 4 elevated tramsaminases 
(18%), and VOD (9%).36
Stone et al in 2004, in a CALGB study, evaluated the 
efﬁ  cacy of treating patients with relapsed or refractory 
AML with high-dose ara-C (HiDAC) in combination with 
GO at different doses (9 or 4.5 mg/m2). The median age was 
64 years. In the initial cohort of patients treated with HiDAC 
3.0 g/m2 (over 3 hours daily for 5 days) and GO 9 mg/m2 
(on day 1) and 4.5 mg/m2 (on day 8) signiﬁ  cant toxicity 
was seen; 8 of the 9 patients died during induction therapy. 
In the phase II study, 44 patients were treated with HiDAC 
3.0 g/m2 (over 3 hours daily for 5 days) and GO at 9 mg/m2 
(on day 7). Seven (19%) achieved CR and two (5%) achieved 
CRp. None of these patients developed VOD.37
Recently, Doyen et al evaluated the efficacy of GO 
and cytarabine in older patients with relapsed or refractory 
AML. Fourteen patients were included in the study and 
the median age was 70 years. Seven patients had de novo 
AML and 7 had secondary AML. All patients received GO 
(6 mg/m2 on day 1 and 4 mg/m2 on day 8) and cytarabine 
(100 mg/m2/24 hours on days 1–7). Two patients achieved 
CR, one achieved CRp, and one achieved PR with an overall 
response rate of 28%. The median OS was 4.6 months. 
Treatment-related death occurred in 4 (28%) patients.38
Fianchi et al evaluated the efﬁ  cacy of GO in combina-
tion with ara-C and G-CSF (G-AraMy regimen) in the 
treatment of elderly patients with poor-prognosis AML. 
Fifty-three patients, with either untreated or relapsed/primary 
refractory AML, were included in this study. The median 
age was 69 years. The OR rate was 57%. Twenty-three 
patients (43%) achieved CR and 1 patient (2%) achieved 
CRp. Eleven patients (21%) achieved PR and, following 
consolidation, 10 patients achieved CR. Median DFS was 
8 months (range or 2–23 + months) and OS was 9 months 
(range 2–24 + months). The most common side effect 







GO dose CR/CRp Median OS 
(months)
Tsimberidou et al36 32 53 (18–78) Fludarabine, Ara-C, 
cyclosporine
4.5 mg/m2 on day 1 9/2 5.3
Chevallier et al40 62 55.5 (16–71) Mitoxantrone, Ara-C 9 mg/m2 on day 4 31/8 9.5
Stone et al37 44 64 (55–69) HiDAC 9 mg/m2 on day 7 7/2 Not yet reported
Cortes et al54 17 55 (23–75) Topotecan, 
cytarabine
9 mg/m2 on day 1 2/0 8.2 weeks
Alvarado et al55 14 61 (34–74) Idarabucin, 
cytarabine
6 mg/m2 on days 1 
and 15
3/3 2
Fianchi et al39 53 69 (65–77) Cytarabine, G-CSF 6 mg/m2 on day 9 23/1 9
Abbreviations: GO, gemtuzumab ozogamicin; CR, complete remission; CRp, complete remission with incomplete platelet recovery; OS, overall survival; RFS, relapse-free 
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was myelosuppression. This study is also interesting in that 
these responses were obtained without the use of anthracy-
clines, which can be especially toxic to older patients. Seven 
patients (13%) died during induction. The authors concluded 
that G-AraMy could be a useful treatment approach, with 
acceptable toxicity, for poor-risk elderly AML patients.39
In a phase II study by Chevallier et al GO was combined 
with intermediate doses of ara-C and mitoxantrone (MIDAM 
regimen). Sixty-two patients were included in the study 
(18 patients with refractory disease and 44 patients with 
relapsed disease). The median age was 55.5 years, 22 patients 
were 60 years of age or older. The MIDAM regimen consisted 
of GO (9 mg/m2) on day 4, cytarabine (1 g/m2) every 12 hours 
on days 1 through 5, and mitoxantrone (12 mg/m2/day) on 
days 1 through 3. The median duration of follow-up was 
26.5 months. The overall response rate was 63%; 31 (50%) 
patients achieved CR and 8 (13%) patients achieved CRp. 
Of those achieving CR or CRp, 15 (24%) were 60 years of 
age or older. Grade 3 to 4 hyperbilirubinemia occurred in 
16% of patients and 3% developed VOD.40
GO as front-line therapy in older 
adults with AML
There are several studies that have evaluated the efﬁ  cacy 
of GO in untreated AML. A phase II trial evaluating the 
efﬁ  cacy of GO as monotherapy for induction, consolidation, 
and maintenance therapy was done by Nabhan et al in 2005. 
Twelve patients were included in the study. All were over the 
age of 65 years and none had received any prior treatment for 
AML. Standard doses of GO (9 mg/m2) were used as induc-
tion therapy. For consolidation, GO (6 mg/m2) was given 
45 to 60 days after chemotherapy and following recovery of 
peripheral counts. For maintenance, GO (3 mg/m2) was given 
every 4 weeks for 4 cycles. Three (27%) patients achieved 
CR. The toxicity proﬁ  le was acceptable, with myelosup-
pression being the most common adverse effect. Five of the 
patients had transient elevation of transaminases, but none 
had grade 3 or 4 hyperbilirubinemia. None of the patients 
developed VOD.41
Another study by GIMEMA-European Organization for 
Research and Treatment of Cancer (EORTC) groups inves-
tigated the use of GO as single-agent therapy in induction 
therapy in elderly patients (AML-15B). Patients were eligible 
for the study if they were  75 years of age and had a World 
Health Organization performance score (PS) of 0–2, or an age 
between 61 and 75 years with a WHO PS   2. Over 50% of 
these patients were over the age of 50 years and were deemed 
to be too frail for other therapy. Forty patients received GO 
(9 mg/m2) in two doses given 2 weeks apart. Seven patients 
achieved either a CR or CRp (17%), 24 patients had resistant 
disease (60%), and 7 patients died during induction (17%). 
The median OS was 4.3 months; 1-year survival was 34%; 
and 2-year survival was 7%. Toxicities included myelosup-
pression (a majority of patients), and severe liver toxicity 
(4 patients, only 1 died of fatal VOD). From this study, it 
was concluded that GO given at this dose was too toxic for 
patients over the age of 75 years and dose-reduction should 
be strongly considered.42
Estey et al evaluated GO with or without interleukin 
11 (IL-11) compared to patients who had received idarubicin 
and continuous-infusion, high-dose cytarabine (IA). Fifty-one 
patients were included in the study and the median age was 
72 years. Patients were randomized to received induction 
therapy with GO (9mg/m2 on days 1 and 8) with or without 
IL-11 (15 μg/kg on days 3–28). Two of 26 patients who 
received GO achieved CR. Nine of 25 patients who received 
GO and IL-11 achieved CR. This was compared to patients 
who had received IA. Patients who had received IA demon-
strated higher CR rate and survival rates.43
Clavio, et al evaluated the efﬁ  cacy of adding low-dose 
GO to ﬂ  udarabine, ara-C, and idarubicin (MY-FLAI regi-
men) in patients with newly diagnosed CD33+ AML. This 
was a prospective, multi-center trial in comparison with a 
historical cohort of patients who had received FLAI, with-
out GO. Forty-six patients were treated with MY-FLAI and 
compared with a historical cohort of 47 patients (matched for 
age and cytogenetics) who received FLAI. The median age 
was 66 years. There was no signiﬁ  cant difference in CR rate 
between the groups. However, patients with de novo AML 
receiving GO had lower risk of relapse at 2 years (40% vs 
80%, p = 0.01) and also demonstrated signiﬁ  cantly better 
overall survival (40% vs 14%, p = 0.02). A higher incidence 
of induction-related deaths were actually reported in the his-
torical cohort of patients only receiving GO than compared 
to those who received the MY-FLAI regimen. This data 
suggested that adding GO might prolong DFS, particularly 
in patients with de novo AML, with acceptable toxicity.44
In another phase II study, Nand et al reported on the use 
of a combination of hydroxyurea, azacitidine, and low-dose 
GO in elderly patients with untreated non-M3 AML and 
high-risk MDS. Twenty patients were enrolled in the study 
(17 patients had AML and 3 had MDS RAEB II). The median 
age was 76 years. The hydroxyurea was administered in order 
to reduce the white blood cell count to below 10,000/μL and 
allow for a lower GO dose (3 mg/m2), in attempts to decrease 
toxicity. Eleven patients (55%) achieved a CR and 3 achieved Clinical Interventions in Aging 2009:4 203
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CRp (15%). The median DFS was 8 months and median OS 
was 10 months. Only 1 patient died early on due to disease 
progression. A majority of these patients were able to be 
treated in the outpatient setting.45
GO in older adults with APL
In patients with acute promyelocytic leukemia (APL), the 
addition of GO can produce molecular remission. APL 
blasts typically have high expressions of CD33 antigen and 
they also have low levels of P-glycoprotein (Pgp), which 
is a product of the MDR1 gene which is a known mediator 
of multidrug resistance. GO has been found to be highly 
effective in treating patients with APL in relapse, and is an 
active area of research to avoid the use of anthracyclines and 
cytarabine, a particularly appealing approach for the rare 
older adult with APL.
Lo-Coco et al evaluated GO as monotherapy for molecu-
larly relapsed APL. Among 16 patients included in the study, 
7 were older than 65 years of age. All patients had received 
prior therapy of ATRA and anthracycline-based therapy with 
cytarabine. All patients had demonstrated molecular relapse. 
These patients were treated with GO at 6 mg/m2 on days 1 
and 15. Fourteen (88%) patients responded and 7 (44%) of 
these patients remained in sustained molecular remission for 
median of 15 months. The estimated OS after ﬁ  rst GO treat-
ment was 74% and molecular RFS was 43%. These results 
supported that GO could be used as monotherapy in patients 
with molecular relapse of APL.46
Estey et al evaluated GO and all-trans retinoic acid 
(ATRA) in patients with previously untreated APL. GO 
was administered at a dose of 9 mg/m2 on day 1 or day 5 of 
therapy. Nineteen patients were included in the study. Three 
patients also received idarubicin due to elevated white blood 
count   30,000. Once CR was achieved, patients received 
8 courses of GO (9 mg/m2 every 4–5 weeks) and ATRA. If 
there was persistent or recurrent polymerase chain reaction 
(PCR) positivity, idarubicin was added to the maintenance 
regimen. Sixteen of the nineteen (84%) patients achieved 
CR. Fourteen of the 16 (88%) patients given GO and ATRA 
without idarubicin achieved CR. GO was well tolerated. 
These data suggested that GO could be effective therapy in 
patients with untreated APL.47
Estey et al also investigated the efﬁ  cacy of GO combined 
with ATRA versus arsenic trioxide (ATO) and ATRA in 
patients with previously untreated APL. Among 44 patients 
with a median age of 49 years, 25 low-risk patients received 
ATO and ATRA for induction and, after achieving CR, 
received ATO plus ATRA without chemotherapy, while 
19 high-risk patients received the identical treatment, but also 
received GO (9 mg/m2) on day 1 of induction. Thirty-nine of 
the 44 patients achieved CR (24 of 25 in the low-risk, 15 of 
19 in the high-risk). These results suggest that ATRA plus ATO 
may be an effective alternative to chemotherapy in patients 
with low-risk, previously untreated APL. It also suggests that 
ATRA plus ATO in combination with GO may be beneﬁ  cial 
in patients with high-risk, previously untreated APL.48
Aribi et al investigated efﬁ  cacy of GO in combination 
with ATO and ATRA in patients with APL in ﬁ  rst relapse. 
Eight patients were enrolled in the study. Two (25%) patients 
were greater than 60 years. All patients had received previ-
ous treatment with ATRA as single-agent or in combina-
tion with other chemotherapy. Seven of these patients had 
hematologic relapse, and one had a molecular relapse. All 
patients achieved molecular CR. After a median follow-up of 
 36 months, 6 patients remained alive in CR and 2 patients 
died in CR. Of the 2 patients who died, 1 died due to com-
plications of metastatic lung adenocarcinoma, and the other 
of sepsis.49
Interestingly, in these patients with APL, the side effects 
were minimal and no cases of VOD have been reported.49
Resistance to GO
Sensitivity to GO and mechanisms of resistance to GO 
continue to be investigated. Initial in vitro investigations 
with GO were performed on 4 different human AML lines 
(KG1, THP-1, HL-60, and NB4) and subsequently in pri-
mary samples from patients with AML. GO was found to 
produce three different responses in AML cell lines: arrest in 
G2 phase of cell cycle followed by apoptosis, G2 arrest with 
little apoptosis, and resistance to high doses of GO. These 
different responses did not correlate with CD33 expression 
or multiple drug resistance (MDR) protein expression.50
Recently, CD33 expression and P-glycoprotein 
(P-gp)-mediated drug efﬂ  ux have been shown to inversely 
correlate with response to GO. In this particular study by 
Water et al, CD33 expression and P-gp activity were found 
to be inversely correlated. Also, patients with lower P-gp 
activity demonstrated greater response to GO51 However, it is 
possible that the effect against GO and calicheamicin occurs 
through other antiapoptotic mechanisms as well.52
Other approaches to relapsed 
AML in older adults
There are several other therapy approaches currently being 
investigated in older adults. Clofarabine, a purine nucleoside 
analog, is being studied as front-line therapy in older patients Clinical Interventions in Aging 2009:4 204
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with AML. Decitabine and azacitidine are hypomethylating 
agents also being studied in de novo and relapsed AML. 
FLT3 ITD mutations, as mentioned before, have been found 
to be present in up to one-third of AML cell lines. These 
mutations result in unregulated cell proliferation. There are 
several oral FLT3 inhibitors that are currently under clinical 
investigation in relapsed/refractory AML and front-line in 
older patients who are considered “unﬁ  t” for intensive che-
motherapy. Tipifarnib, an oral farnesyltransferase inhibitor 
(FTI), has also been studied in older patients with refractory 
or relapsed AML. FTIs are selective inhibitors of intracel-
lular farnesyltransferase, which is an enzyme that catalyzes 
transfer of farnesyl to cysteine terminal residue of various 
substrate proteins (including oncoprotein Ras and several 
others). These inhibitors subsequently inhibit cellular sig-
naling transduction pathways and can potentially inhibit 
tumor growth.
Conclusions
GO is a humanized anti-CD33 monoclonal antibody therapy 
that has been shown to be affective and well tolerated in the 
older adult population. It has acceptable toxicity proﬁ  le; the 
main adverse effects include infusion-related events, severe 
myelosuppression, and hepatotoxicity (including VOD). GO 
is an important new anti-leukemic therapy and has promis-
ing efﬁ  cacy in both de novo and relapsed disease. It will 
be important to better deﬁ  ne the population of patients that 
would beneﬁ  t most from this targeted therapy. Also, the role 
of GO in monotherapy or in combination therapy regimens 
for the treatment of AML needs to be further investigated.
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